| 000 | 01860 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515121516.0 | ||
| 264 | 0 | _c20080818 | |
| 008 | 200808s 0 0 eng d | ||
| 022 | _a1078-0432 | ||
| 024 | 7 |
_a10.1158/1078-0432.CCR-07-4079 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBerger, Raanan | |
| 245 | 0 | 0 |
_aPhase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. _h[electronic resource] |
| 260 |
_bClinical cancer research : an official journal of the American Association for Cancer Research _cMay 2008 |
||
| 300 |
_a3044-51 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aAntigens, CD _xmetabolism |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aApoptosis Regulatory Proteins _xmetabolism |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHematologic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProgrammed Cell Death 1 Receptor |
| 700 | 1 | _aRotem-Yehudar, Rinat | |
| 700 | 1 | _aSlama, Gideon | |
| 700 | 1 | _aLandes, Shimon | |
| 700 | 1 | _aKneller, Abraham | |
| 700 | 1 | _aLeiba, Merav | |
| 700 | 1 | _aKoren-Michowitz, Maya | |
| 700 | 1 | _aShimoni, Avichai | |
| 700 | 1 | _aNagler, Arnon | |
| 773 | 0 |
_tClinical cancer research : an official journal of the American Association for Cancer Research _gvol. 14 _gno. 10 _gp. 3044-51 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1078-0432.CCR-07-4079 _zAvailable from publisher's website |
| 999 |
_c17977882 _d17977882 |
||